- Swissmedic clears Novartis' (NYSE:NVS) Entresto (sacubitril/valsartan), previously LCZ696, to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduce ejection fraction. About 150K people in Switzerland live with heart failure.
- The FDA approved Entresto in July.